Investor · 2 deals
Every published round Sanofi Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| AdvanCell | Series D+ | 15 Jul 2026 | $450m | Participant | Forbes Australia (3 Sep 2026), Forbes Australia (16 Jul 2026), Brandon Capital, advancell.com.au, Brandon Capital portfolio, Brandon Capital portfolio, Tenmile portfolio | |
| AdvanCell | Series C | 12 Feb 2025 | $178m | Lead | Forbes Australia, SmartCompany, Startup Daily, Brandon Capital |
Companies Sanofi Ventures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AdvanCell | Produces radiopharmaceuticals that target cancer cells without the typical collateral dam… | 12 Feb 2025, Series C | 2 | 1 |
Fund closes reported for Sanofi Ventures, as distinct from the investments it has made.
Companies Sanofi Ventures has backed that another company then bought. An exit for the holding, not a deal Sanofi Ventures did.
Stories naming Sanofi Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brisbane radiopharmaceutical developer AdvanCell has closed an oversubscribed Series D round, led by Ally Bridge Group and Alpha Wave with several institutional investors returning, to fund late-stage prostate cancer trials and US manufacturing.
Sydney cancer-therapy developer AdvanCell has completed a US$112 million Series C that was oversubscribed, co-led by four investors, with Brandon Capital among new backers; three investor representatives join the board.